Get the Stockscreener App
1.05
1.94%
0.02
Galmed Pharmaceuticals Ltd stock is traded at $1.05, with a volume of 89,129.
It is up +1.94% in the last 24 hours and down -8.70% over the past month.
Galmed Pharmaceuticals Ltd is a biopharmaceutical company. It focuses on the development of Aramchol. exclusively on developing Aramchol for the treatment of liver disease and were previously developing Aramchol for primary sclerosing cholangitis, PSC, and exploring the feasibility of developing Aramchol for other fibro-inflammatory indications outside of NASH and fibrosis. The company is currently seeking to advance the development of Aramchol for oncological indications outside of NASH and fibrosis.
See More
Previous Close:
$1.03
Open:
$1.06
24h Volume:
89,129
Relative Volume:
0.05
Market Cap:
$5.75M
Revenue:
-
Net Income/Loss:
$-8.72M
P/E Ratio:
-0.1914
EPS:
-5.4871
Net Cash Flow:
$-5.47M
1W Performance:
-6.25%
1M Performance:
-8.70%
6M Performance:
-34.78%
1Y Performance:
-62.70%
1-Day Range:
$1.02
$1.07
1-Week Range:
$1.015
$1.21
52-Week Range:
$0.7449
$3.61
Galmed Pharmaceuticals Ltd Stock (GLMD) Company Profile
Name
Galmed Pharmaceuticals Ltd
Sector
Industry
Phone
-
Address
-
Compare GLMD with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GLMD
Galmed Pharmaceuticals Ltd
|
1.05 | 5.64M | 0 | -8.72M | -5.47M | -5.4871 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Galmed Pharmaceuticals Ltd Stock (GLMD) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| May-22-20 | Downgrade | B. Riley FBR | Buy → Neutral |
| Feb-04-20 | Initiated | Craig Hallum | Buy |
| Jan-30-20 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-02-19 | Initiated | Canaccord Genuity | Buy |
| Dec-12-18 | Initiated | B. Riley FBR | Buy |
| Aug-02-18 | Reiterated | Maxim Group | Buy |
| Jul-13-18 | Initiated | Stifel | Buy |
| Jul-12-18 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-12-18 | Reiterated | H.C. Wainwright | Buy |
| Mar-15-18 | Upgrade | Maxim Group | Hold → Buy |
| Feb-14-18 | Downgrade | Maxim Group | Buy → Hold |
| Feb-12-18 | Reiterated | H.C. Wainwright | Buy |
| Nov-15-17 | Initiated | ROTH Capital | Buy |
| Aug-08-17 | Reiterated | H.C. Wainwright | Buy |
| Jul-31-17 | Reiterated | Maxim Group | Buy |
| Aug-01-16 | Reiterated | Maxim Group | Buy |
| Jul-06-16 | Resumed | ROTH Capital | Buy |
| Mar-28-16 | Resumed | H.C. Wainwright | Buy |
| Jun-23-15 | Initiated | H.C. Wainwright | Buy |
| May-06-15 | Initiated | Sun Trust Rbsn Humphrey | Buy |
View All
Galmed Pharmaceuticals Ltd Stock (GLMD) Latest News
Galmed to present data on Aramchol’s potential in liver cancer By Investing.com - Investing.com Canada
Galmed to present data on Aramchol’s potential in liver cancer - Investing.com
Galmed Pharmaceuticals’ Aramchol Abstract Accepted for HEP-DART 2025 Presentation - TipRanks
Galmed Announces Acceptance of a Late-Breaking Abstract to be Presented at HEP-DART 2025 Meeting - Yahoo Finance
Galmed receives patent for combination therapy in South Korea By Investing.com - Investing.com Nigeria
Can Galmed Pharmaceuticals Ltd. (GPH) stock surprise with quarterly resultsBuy Signal & Weekly Breakout Watchlists - Newser
Galmed Announces Grant of New Use Patents for the Combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra for Mash - marketscreener.com
Galmed stock rises after patent grant for MASH combo therapy By Investing.com - Investing.com Nigeria
Galmed stock rises after patent grant for MASH combo therapy - Investing.com
Galmed receives patent for combination therapy in South Korea - Investing.com
Galmed Pharmaceuticals Secures New Patent for Aramchol Combination Therapy - TipRanks
Galmed announces grant of new use patents for the combination of Aramchol and Madrigal Pharmaceuticals - marketscreener.com
Galmed Announces Grant of New Use Patents for the combination of Aramchol and Madrigal Pharmaceuticals' Rezdiffra (Resmetirom) for MASH - WV News
Can Galmed Pharmaceuticals Ltd. (GPH) stock sustain free cash flowQuarterly Trade Review & Accurate Trade Setup Notifications - Newser
Galmed Pharmaceuticals (NASDAQ:GLMD) Stock Passes Below 200-Day Moving Average – Should You Sell? - Defense World
Is Galmed Pharmaceuticals Ltd. (GPH) stock supported by strong fundamentals2025 EndofYear Setup & Risk Managed Investment Signals - Newser
Is Galmed Pharmaceuticals Ltd. (GPH) stock good for long term investing - Newser
Can Galmed Pharmaceuticals Ltd. (GPH) stock attract ESG investmentsTrade Volume Summary & High Accuracy Investment Signals - Newser
Galmed Pharmaceuticals Shares Edge Higher Following CEO’s Positive Update - MSN
Galmed Pharmaceuticals Expands Aramchol’s Clinical Applications and Strengthens Financial Position - MSN
Is Galmed Pharmaceuticals Ltd. (GPH) stock positioned for digital growth era2025 Trading Volume Trends & Real-Time Buy Signal Notifications - Newser
Galmed reports $19.2 million cash position, advances Aramchol programs By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook By Investing.com - Investing.com Nigeria
Galmed Pharmaceuticals stock rises on CEO’s optimistic outlook - Investing.com
Galmed reports $19.2 million cash position, advances Aramchol programs - Investing.com
Galmed Issues CEO Letter to Shareholders - Sahm
Galmed Pharmaceuticals (GLMD) Stock Analysis Report | Financials & Insights - Benzinga
What drives Galmed Pharmaceuticals Ltd stock priceEx-Dividend Date Alerts & Fast Growing Portfolio Trading - earlytimes.in
Is Galmed Pharmaceuticals Ltd. stock a defensive play in 2025Quarterly Trade Report & Consistent Profit Trading Strategies - BỘ NỘI VỤ
Energy Moves: How interest rate cuts could boost Galmed Pharmaceuticals Ltd. stockJuly 2025 Institutional & High Accuracy Trade Signal Alerts - moha.gov.vn
EV Market: How Galmed Pharmaceuticals Ltd. stock compares to growth peersJuly 2025 Action & Fast Gaining Stock Reports - BỘ NỘI VỤ
Galmed Pharmaceuticals Ltd (GLMD) Clearly Signals Buy-Into the Stock: Don’t ignore the signals - Setenews
Galmed Pharmaceuticals: Q3 Earnings Snapshot - Stamford Advocate
How Galmed Pharmaceuticals Ltd. stock compares to growth peersJuly 2025 Fed Impact & Capital Protection Trade Alerts - BỘ NỘI VỤ
Galmed Pharmaceuticals Reports Q3 2025 Financials and Research Breakthroughs - TipRanks
Galmed Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update - PR Newswire
Will Galmed Pharmaceuticals Ltd. stock outperform tech sector in 2025July 2025 Opening Moves & AI Forecast for Swing Trade Picks - BỘ NỘI VỤ
MSN Money - MSN
Galmed Pharmaceuticals Ltd. (GLMD) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Key metrics from Galmed Pharmaceuticals Ltd.’s quarterly dataJuly 2025 Sector Moves & Verified Stock Trade Ideas - newser.com
Can swing trading help recover from Galmed Pharmaceuticals Ltd. lossesTrade Ideas & Daily Profit Maximizing Tips - newser.com
Is Galmed Pharmaceuticals Ltd. (GPH) stock resilient in recession scenarios - newser.com
Galmed Pharmaceuticals Ltd Stock (GLMD) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):